Pharma's Market
SPECIAL REPORT
MOST SHARED
- Public Pensions Faulted for Bets on Rosy Returns
- Greece to Leave Euro Zone on June 18: Wealth Manager
- Banks Recapitalization Is a 'Necessary Evil': Strategist
- Winemaking Lures the Wealthy, But Not With Profits
- Italy 2-Year Borrowing Costs at Peak Since December
- Euro Rallies as Greece's Pro-Bailout Parties Gain Favor
- European Firms Plan for Greek Unrest and Euro Exit
- Will the Euro Misery Give Rise to Another Soros?
- Olive Oil Price Dip Adds to European Woes
- Europe’s Stronger Powers Must Reveal Plans: Ex-BoE Official
- A New Look at the ‘New Poor’
- Six Pack: Beer Buzz of the Week
- Greek Exit Could Trigger 50% Fall in Euro Stocks: Analyst
- Under Pressure, FHA Skews to Wealthier Home Buyers
- Big Stock Upside for Hudson City Deal: Analyst
- 5 High-Yield Stocks Ready to Boost Dividends
- Yoshikami: Four Things You Need to Know About Gold Now
- Steinbock: The Euro Zone Endgame Begins
- Option Bulls Take Another Shot on Idenix
- European Companies Plan for Greek Unrest and Euro Exit
- Public Pensions Faulted for Bets on Rosy Returns
- Will the Euro Misery Give Rise to Another Soros?
- Greece to Leave Euro Zone on June 18: Wealth Manager
- Italy 2-Year Borrowing Costs at Peak Since December
- Euro Bond Wins Supporters, but Details Remain Vague
- German, UK Bond Yields Will Go Even Lower
- Labor Board Member Resigns Over Leak to GOP Allies
- Banks Recapitalization Is a 'Necessary Evil': Strategist
RSS FEED
The Boston Scientific Tobin Party
Text Size 
Reporter
 |
CNBC.com |
Shares of several of the big medical device makers are participating in today's rally, so it's hard to tell if Boston Scientific [BSX
Loading...
()
] is just getting swept up in that or whether the fact that it's among the most actively traded stocks on the NYSE and the biggest percentage gainer in the group is due to its news today.
After 10 years at the helm, BSX CEO Jim Tobin is retiring and the former Chairman and CEO of Zimmer Holdings [ZMH
Loading...
()
], which makes replacement parts for people, will take his place on July 13th.
Boston Scientific has been locked in an intense battle in the increasingly competitive drug-coated stent market. Those are the little wire mesh tubes that prop open clogged arteries. And it's successful, but hard-fought takeover duel with Johnson & Johnson [JNJ
Loading...
()
] for Guidant didn't turn out so well. Just this week, though, BSX announced study results that many analyst believe could reinvigorate sales growth for the implantable heart devices BSX got from Guidant.
JPMorgan MedTech analyst Mike Weinstein says, "We expect this morning's announcement, while sudden and surprising to the Street, to be positive for the stock, given Elliott's track record at ZMH of creating shareholder value." And Rick Wise at Leerink Swann says, "We believe Elliott is a highly experienced and energetic executive, capable of effecting positive change and driving progress at BSX." JPM has banked BSX and wants to do it again soon.
I've never met Elliott and I never covered ZMH when he was there. I just hope he's more media and TV friendly than Tobin who has kept a very low profile. Despite repeated invitations, he hasn't done an interview with me or appeared on CNBC in years. Over Tobin's decade-long reign BSX shares have been cut in half. ZMH shares more than doubled under Elliott. Investors are clearly hoping he can do that again.
Questions? Comments? and follow me on Twitter at mhuckman
Data is a real-time snapshot *Data is delayed at least 15 minutes
